| Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma |
Ongoing |
Sorafenib (Nexavar) |
3 |
RTOG 1112 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY |
Terminated |
Risdiplam |
2 |
BN40703 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease |
Ongoing |
Ozanimod HCl |
3 |
RPC01-3203 |
King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer |
Ongoing |
DOCETAXEL, Paclitaxel, TAMOXIFEN and Letrozole |
3 |
S1007 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Study of Aflibercept in Uveitic Macular EDema (SAUD study) |
Rejected |
Aflibercept |
3 |
18176/ |
King Khaled Eye Specialist Hospital (Riyadh) |
| A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer |
Ongoing |
CISPLATIN (CISPLATYL ) |
2 |
NRG-HN002 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase Ib study to determine the safety and immunogenicity of the candidate Middle East Res-piratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers |
Ongoing |
vaccine ChAdOx1 MERS |
1 |
CT18/004/R |
King Abdulaziz Medical City NG (Riyadh) |
| Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease. |
Ongoing |
Ozanimod HCl |
3 |
RPC01-3201 |
King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia |
Rejected |
Dasatinib |
2 |
LPI-JOR-LEB-KSA-TUN- |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease |
Ongoing |
Ozanimod HCl |
3 |
RPC01-3204 |
King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
